U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    STK17A serine/threonine kinase 17a [ Homo sapiens (human) ]

    Gene ID: 9263, updated on 27-Nov-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells.

    Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells.
    Pang K, Lee J, Kim J, Park J, Park Y, Hong E, An H, Ooshima A, Son M, Park KS, Cho JH, Lee C, Song YS, Yang KM, Kim SJ., Free PMC Article

    04/16/2022
    Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration.

    Predictive significance of STK17A in patients with gastric cancer and association with gastric cancer cell proliferation and migration.
    Wang Z, Wang C, Jiang BH, Shi L, Lin S, Wang L, Liu LZ, Qiu JG, Qin Y, Jia Y., Free PMC Article

    11/27/2021
    Genome-wide association study of non-tuberculous mycobacterial pulmonary disease.

    Genome-wide association study of non-tuberculous mycobacterial pulmonary disease.
    Cho J, Park K, Choi SM, Lee J, Lee CH, Lee JK, Heo EY, Kim DK, Lee YJ, Park JS, Cho YJ, Yoon HI, Lee JH, Lee CT, Kim N, Choi KY, Lee KH, Sung J, Won S, Yim JJ.

    07/17/2021
    Destablilization of TRAF6 by DRAK1 Suppresses Tumor Growth and Metastasis in Cervical Cancer Cells.

    Destablilization of TRAF6 by DRAK1 Suppresses Tumor Growth and Metastasis in Cervical Cancer Cells.
    Park Y, Pang K, Park J, Hong E, Lee J, Ooshima A, Kim HS, Cho JH, Han Y, Lee C, Song YS, Park KS, Yang KM, Kim SJ.

    11/21/2020
    Prognostic and predictive roles of microRNA411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer.

    Prognostic and predictive roles of microRNA‑411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer.
    Wei W, Liu C., Free PMC Article

    10/31/2020
    Loss of serine threonine kinase 17A occurs in colorectal cancer metastasis, induces mesenchymal morphologies, and contributes to tumor cell invasion and migration in colorectal cancer.

    Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells.
    Short SP, Thompson JJ, Bilotta AJ, Chen X, Revetta FL, Washington MK, Williams CS., Free PMC Article

    01/11/2020
    High STK17A expression is associated with glioma.

    Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling.
    Chen AS, Wardwell-Ozgo J, Shah NN, Wright D, Appin CL, Vigneswaran K, Brat DJ, Kornblum HI, Read RD., Free PMC Article

    12/21/2019
    These findings suggest that DRAK1 translocates in response to stimuli and induces apoptosis through its interaction with specific binding partners, p53 and/or ANT2.

    Intracellular localization and binding partners of death associated protein kinase-related apoptosis-inducing protein kinase 1.
    Oue Y, Murakami S, Isshiki K, Tsuji A, Yuasa K.

    03/17/2018
    the present study was the first to find localization of STK17A in normal bile canaliculi.

    Abnormal Localization of STK17A in Bile Canaliculi in Liver Allografts: An Early Sign of Chronic Rejection.
    Ozeki M, Salah A, Aini W, Tamaki K, Haga H, Miyagawa-Hayashino A., Free PMC Article

    05/21/2016
    DRAK1 was predominantly localized in the cytoplasm and bound to Smad3, thereby interrupting Smad3/Smad4 complex formation, which is the core process for the induction of tumor suppressor genes by TGF-beta1

    Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-β1 tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4.
    Park Y, Kim W, Lee JM, Park J, Cho JK, Pang K, Lee J, Kim D, Park SW, Yang KM, Kim SJ.

    12/19/2015
    STK17A provides a proliferative and survival advantage to GBM cells

    Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma.
    Mao P, Hever-Jardine MP, Rahme GJ, Yang E, Tam J, Kodali A, Biswal B, Fadul CE, Gaur A, Israel MA, Spinella MJ., Free PMC Article

    12/20/2014
    When analyzing STK17A haplotypes distribution, we found association between TGGTC, TAGTC and AAGAT haplotypes and risk to develop SLE

    Polymorphisms in STK17A gene are associated with systemic lupus erythematosus and its clinical manifestations.
    da Silva Fonseca AM, de Azevedo Silva J, Pancotto JA, Donadi EA, Segat L, Crovella S, Sandrin-Garcia P.

    11/2/2013
    identified STK17A as a novel direct target of p53 and a modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.

    Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.
    Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG, Desai D, Beyrouthy MJ, Kerley-Hamilton JS, Freemantle SJ, Spinella MJ., Free PMC Article

    08/6/2011
    Observational study of gene-disease association. (HuGE Navigator)See all PubMed (2) articles

    An approach based on a genome-wide association study reveals candidate loci for narcolepsy.
    Shimada M, Miyagawa T, Kawashima M, Tanaka S, Honda Y, Honda M, Tokunaga K.

    The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.
    Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Pérez L, Schiavi F, Leskelä S, Pita G, Milne R, Maravall J, Ramos I, Andía V, Rodríguez-Poyo P, Jara-Albarrán A, Meoro A, del Peso C, Arribas L, Iglesias P, Caballero J, Serrano J, Picó A, Pomares F, Giménez G, López-Mondéjar P, Castello R, Merante-Boschin I, Pelizzo MR, Mauricio D, Opocher G, Rodríguez-Antona C, González-Neira A, Matías-Guiu X, Santisteban P, Robledo M.

    12/2/2009
    firstprevious page of 1 nextlast